Fennec Begin Period Cash Flow from 2010 to 2024
| FENC Stock | USD 6.06 0.05 0.83% |
Begin Period Cash Flow | First Reported 2001-09-30 | Previous Quarter 51.1 M | Current Value 43 M | Quarterly Volatility 10.5 M |
Check Fennec Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Fennec Pharmaceuticals' main balance sheet or income statement drivers, such as Discontinued Operations of 0.0, Depreciation And Amortization of 272.6 K or Interest Expense of 3.6 M, as well as many indicators such as Price To Sales Ratio of 13.33, Dividend Yield of 0.0 or Days Sales Outstanding of 144. Fennec financial statements analysis is a perfect complement when working with Fennec Pharmaceuticals Valuation or Volatility modules.
Fennec | Begin Period Cash Flow |
Latest Fennec Pharmaceuticals' Begin Period Cash Flow Growth Pattern
Below is the plot of the Begin Period Cash Flow of Fennec Pharmaceuticals over the last few years. It is the amount of cash a company has at the beginning of a financial reporting period. It serves as the starting point for calculating the period's cash flow from operations, investing, and financing activities. Fennec Pharmaceuticals' Begin Period Cash Flow historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Fennec Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
| Begin Period Cash Flow | 10 Years Trend |
|
Begin Period Cash Flow |
| Timeline |
Fennec Begin Period Cash Flow Regression Statistics
| Arithmetic Mean | 12,489,566 | |
| Geometric Mean | 5,820,728 | |
| Coefficient Of Variation | 91.08 | |
| Mean Deviation | 10,325,965 | |
| Median | 5,947,000 | |
| Standard Deviation | 11,375,155 | |
| Sample Variance | 129.4T | |
| Range | 30.3M | |
| R-Value | 0.81 | |
| Mean Square Error | 48T | |
| R-Squared | 0.66 | |
| Significance | 0.0003 | |
| Slope | 2,058,926 | |
| Total Sum of Squares | 1811.5T |
Fennec Begin Period Cash Flow History
About Fennec Pharmaceuticals Financial Statements
Fennec Pharmaceuticals stakeholders use historical fundamental indicators, such as Fennec Pharmaceuticals' Begin Period Cash Flow, to determine how well the company is positioned to perform in the future. Although Fennec Pharmaceuticals investors may analyze each financial statement separately, they are all interrelated. For example, changes in Fennec Pharmaceuticals' assets and liabilities are reflected in the revenues and expenses on Fennec Pharmaceuticals' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Fennec Pharmaceuticals. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Begin Period Cash Flow | 23.8 M | 25 M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Fennec Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Fennec Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Fennec Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Fennec Pharmaceuticals Stock:Check out the analysis of Fennec Pharmaceuticals Correlation against competitors. For information on how to trade Fennec Stock refer to our How to Trade Fennec Stock guide.You can also try the Price Exposure Probability module to analyze equity upside and downside potential for a given time horizon across multiple markets.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Fennec Pharmaceuticals. If investors know Fennec will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Fennec Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.04) | Revenue Per Share 1.814 | Quarterly Revenue Growth 0.07 | Return On Assets 0.027 | Return On Equity (10.06) |
The market value of Fennec Pharmaceuticals is measured differently than its book value, which is the value of Fennec that is recorded on the company's balance sheet. Investors also form their own opinion of Fennec Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Fennec Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Fennec Pharmaceuticals' market value can be influenced by many factors that don't directly affect Fennec Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Fennec Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Fennec Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Fennec Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.